ImmunityBio (IBRX) net assets (shareholders' equity)

Net assets · fiscal 2025
-$500.47M

ImmunityBio (IBRX) had net assets of -$500.47M at the end of fiscal 2025 (December 31, 2025). In fiscal 2024 the figure was -$489.10M. Figures as of 19 Nov 2026, 11:31 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
-$500.47M
Highest on record
$356.00Mfiscal 2015
Lowest on record
-$586.99Mfiscal 2023
Fiscal years on record
132013–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

ImmunityBio net assets (shareholders' equity), in more detail

Across the 13 fiscal years on record (2013–2025), the highest was $356.00M in fiscal 2015 and the lowest -$586.99M in fiscal 2023.

History · 13 fiscal years

Net assets by fiscal year

ImmunityBio net assets (shareholders' equity), year by year

ImmunityBio (IBRX) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025-$500.47M—
2024-$489.10M—
2023-$586.99M—
2022-$447.33M—
2021-$242.17M—
2020-$119.81M 199.3% down
2019$120.68M 17.3% down
2018$146.01M 33.3% down
2017$218.84M 25.4% down
2016$293.42M 17.6% down
2015$356.00M 518.1% up
2014$57.59M—
2013-$3.76M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of ImmunityBio and comparable companies
CompanyNet assetsFiscal year
Alkermes ALKS$1.82B2025
PACS Group PACS$946.77M2025
Kiniksa Pharmaceuticals International KNSA$567.61M2025
ImmunityBio IBRX-$500.47M2025
Cytokinetics CYTK-$659.63M2025
ABIVAX ABVX€455.21M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on IBRX

ImmunityBio, figure by figure

ImmunityBio (IBRX) overview: price, valuation and scorecardAll health care companies by market value

ImmunityBio net assets (shareholders' equity): questions and answers

What are ImmunityBio's net assets?

ImmunityBio (IBRX) had net assets of -$500.47M at the end of fiscal 2025 (December 31, 2025). In fiscal 2024 the figure was -$489.10M.

What are the highest and lowest net assets figures on record for ImmunityBio?

Across the 13 fiscal years on record (2013–2025), the highest was $356.00M in fiscal 2015 and the lowest -$586.99M in fiscal 2023.

How is ImmunityBio's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For ImmunityBio it is on record here for 13 fiscal years, 2013 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “ImmunityBio (IBRX) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/IBRX/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.